生命科学资讯

Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset

Roche to invest $478 million in Korea clinical trials over 5 years - koreabiomed.com

Roche to invest $481 mn in South Korea clinical trials, biotech partnerships - The Korea Economic Daily Global Edition

News | Biotech giant recommits to major Wisconsin hub despite cuts across US office portfolio - CoStar

10x Genomics at TD Cowen Conference: Navigating Challenges with Strategic Initiatives - Investing.com India

Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivant

Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Old school healthcare is warming up to tech

[Form 4] AGILENT TECHNOLOGIES, INC. Insider Trading Activity - Stock Titan

Prime Medicine reverses course to seek FDA approval of shelved therapy

After years of dispute with FDA, Vanda will get a public hearing for jet lag drug

Kyowa Kirin ends OX40 trials after Amgen balked, safety concern

New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program

Theravance halves headcount, ends all R&D work after phase 3 rare disease fail

FDA details rationale for rejecting rare disease gene therapy from Regenxbio

FDA explains how some copycat drugs can still win three years of exclusivity

Agilent Technologies (A) Analyst Rating Update: Morgan Stanley L - GuruFocus

[144] THERMO FISHER SCIENTIFIC INC. SEC Filing - Stock Titan

Kyowa Kirin abandons touted eczema drug following safety review

Morgan Stanley Lowers Agilent Technologies (NYSE:A) Price Target to $160.00 - MarketBeat